Advances In Research On Synergism Of Chemoradiotherapy And Immunotherapy For Glioblastoma

The current standard of care for glioblastoma(GBM) is maximal surgical resection with adjuvant chemoradiotherapy.But the 5-year survival with GBM remains at a dismal <10%.Immunotherapies such as the dendritic cell(DC) vaccine,epidermal growth factor receptor(EGFRvIII)vaccine, heat shock protein vaccine and Peptide Vaccines have shown encouraging results in clinical trials, and have demonstrated synergistic effects with chemoradiotherapy in ongoing phase III trials.Cytotoxic ionizing radiation is known to trigger pro-inflammatory signaling cascades and immune activation secondary to cell death, which can then be exploited by immunotherapies. The immunotherapy has developped so much that it will be one of the effective therapies after surgical resection and chemoradiotherapy.The future of GBM therapeutics will involve finding the place for immunotherapy in the current treatment regimen.This article reviews current GBM therapy with it,s abstacle,and the evidences for combination of immune checkpoint inhibitors, DC,EGFRvIII vaccines and Peptide Vaccines with the current chemoradiotherapy.